BRPI1005169A2 - combinação de (a) metotrexato e (b) um inibidor de dhodh não-hepatotóxico, uso de uma combinação, produto, conjunto, embalagem e método de tratamento - Google Patents

combinação de (a) metotrexato e (b) um inibidor de dhodh não-hepatotóxico, uso de uma combinação, produto, conjunto, embalagem e método de tratamento

Info

Publication number
BRPI1005169A2
BRPI1005169A2 BRPI1005169A BRPI1005169A BRPI1005169A2 BR PI1005169 A2 BRPI1005169 A2 BR PI1005169A2 BR PI1005169 A BRPI1005169 A BR PI1005169A BR PI1005169 A BRPI1005169 A BR PI1005169A BR PI1005169 A2 BRPI1005169 A2 BR PI1005169A2
Authority
BR
Brazil
Prior art keywords
combination
nonhephototoxic
methotrexate
kit
package
Prior art date
Application number
BRPI1005169A
Other languages
English (en)
Inventor
Pilar Pizcueta Lalanza Maria
Godessart Marina Nuria
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40790917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1005169(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of BRPI1005169A2 publication Critical patent/BRPI1005169A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
BRPI1005169A 2009-01-21 2010-01-19 combinação de (a) metotrexato e (b) um inibidor de dhodh não-hepatotóxico, uso de uma combinação, produto, conjunto, embalagem e método de tratamento BRPI1005169A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09382006A EP2210615A1 (en) 2009-01-21 2009-01-21 Combinations comprising methotrexate and DHODH inhibitors
PCT/EP2010/000270 WO2010083975A1 (en) 2009-01-21 2010-01-19 Combinations comprising methotrexate and dhodh inhibitors

Publications (1)

Publication Number Publication Date
BRPI1005169A2 true BRPI1005169A2 (pt) 2019-09-24

Family

ID=40790917

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1005169A BRPI1005169A2 (pt) 2009-01-21 2010-01-19 combinação de (a) metotrexato e (b) um inibidor de dhodh não-hepatotóxico, uso de uma combinação, produto, conjunto, embalagem e método de tratamento

Country Status (23)

Country Link
US (1) US20110280831A1 (pt)
EP (2) EP2210615A1 (pt)
JP (1) JP2012515737A (pt)
KR (1) KR20110117658A (pt)
CN (1) CN102292108A (pt)
AR (1) AR075036A1 (pt)
AU (1) AU2010206334A1 (pt)
BR (1) BRPI1005169A2 (pt)
CA (1) CA2748400A1 (pt)
CL (1) CL2011001760A1 (pt)
CO (1) CO6341575A2 (pt)
EA (1) EA201101098A1 (pt)
EC (1) ECSP11011201A (pt)
IL (1) IL213625A0 (pt)
MX (1) MX2011007446A (pt)
NZ (1) NZ593413A (pt)
PE (1) PE20120552A1 (pt)
SG (2) SG196826A1 (pt)
TW (1) TW201029652A (pt)
UA (1) UA104449C2 (pt)
UY (1) UY32380A (pt)
WO (1) WO2010083975A1 (pt)
ZA (1) ZA201104259B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EP2135610A1 (en) * 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
EP2239256A1 (en) 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
EP2314577A1 (en) 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
EP2444086A1 (en) * 2010-10-22 2012-04-25 Almirall, S.A. Combinations comprising DHODH inhibitors and COX inhibitors
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
US20140031383A1 (en) 2011-02-08 2014-01-30 Dana-Farber Cancer Institute, Inc. Methods for treatment of melanoma
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
EP2518071A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
JP6088429B2 (ja) * 2011-08-30 2017-03-01 富山化学工業株式会社 関節リウマチなどの自己免疫疾患の治療の改善方法
WO2014060431A1 (en) 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
UY35332A (es) 2013-02-15 2014-11-28 Almirall Sa Derivados de pirrolotriazina como inhibidores de pi3k
GB201809102D0 (en) 2018-06-04 2018-07-18 Univ Oxford Innovation Ltd Compounds
WO2020067412A1 (ja) 2018-09-28 2020-04-02 富士フイルム株式会社 シタラビンを含む抗腫瘍剤、シタラビンと併用される抗腫瘍効果増強剤、抗腫瘍用キット、およびシタラビンと併用される抗腫瘍剤
EP4037770A1 (en) * 2019-10-04 2022-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Novel pyridin-2(1h)one derivatives, their preparation and their use for the treatment of pain
EP4190402B1 (en) * 2020-07-30 2025-08-27 FUJIFILM Corporation Nitrogen-containing heterocyclic compound or salt thereof, use thereof, and intermediate thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4226869A (en) * 1979-02-02 1980-10-07 American Cyanamid Company Method of stimulating the immune response with halogenated 10-(ω-dialkylaminopolymethyleneamino)-2-methoxypyrido[3,2-b]quinolines
JP3299971B2 (ja) 1995-06-21 2002-07-08 アスタ メディカ アクチエンゲゼルシャフト 一体的に形成された調量装置を備えた薬用粉末カートリッジおよび粉末薬剤吸入器
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US20080268045A1 (en) * 2006-11-09 2008-10-30 Proprius Pharmaceuticals, Inc. Sustained release methotrexate formulations and methods of use thereof
UY31272A1 (es) * 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EP2135610A1 (en) * 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate

Also Published As

Publication number Publication date
MX2011007446A (es) 2011-08-03
WO2010083975A1 (en) 2010-07-29
IL213625A0 (en) 2011-07-31
NZ593413A (en) 2013-12-20
UY32380A (es) 2010-02-26
CO6341575A2 (es) 2011-11-21
PE20120552A1 (es) 2012-05-21
SG172453A1 (en) 2011-07-28
EP2389197B1 (en) 2014-06-18
EA201101098A1 (ru) 2012-01-30
CL2011001760A1 (es) 2012-03-09
TW201029652A (en) 2010-08-16
KR20110117658A (ko) 2011-10-27
ECSP11011201A (es) 2011-08-31
US20110280831A1 (en) 2011-11-17
AR075036A1 (es) 2011-03-02
ZA201104259B (en) 2012-02-29
JP2012515737A (ja) 2012-07-12
EP2389197A1 (en) 2011-11-30
SG196826A1 (en) 2014-02-13
CN102292108A (zh) 2011-12-21
EP2210615A1 (en) 2010-07-28
CA2748400A1 (en) 2010-07-29
UA104449C2 (uk) 2014-02-10
AU2010206334A1 (en) 2011-07-07

Similar Documents

Publication Publication Date Title
IL210843A0 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
DK2276767T3 (da) Benzopyran- og benzoxepinforbindelser som pi3k-inhibitorer og anvendelsesfremgangsmåder
HUE054298T2 (hu) Készítmények és módszerek stroke kezelésére egy konkomittáns sztatin terápián tartott alanyban
DK2121614T3 (da) Aminonikotin og isonikotinsyrederivater som dhodh-inhibitorer
DK2178840T3 (da) Azabiphenylaminobenzoesyre-derivater som dhodh-hæmmere
DK2421825T3 (da) Azetidinyldiamider som monoacylglycerollipase-inhibitorer
IL209267A0 (en) Combinations comprising methotrexate and dhodh inhibitors
BRPI1014316A2 (pt) composição, e, uso de uma composição
EP2272817A4 (en) PAI-1 INHIBITORS
EP2393776A4 (en) NEW TRIFLUOROMETHYLSULFONAMIDE INHIBITOR OF GAMMA-SECRETASE
HUE046951T2 (hu) TFPI-inhibitorok és eljárás alkalmazásukra
BR112013003536A2 (pt) composição, e utilização de uma composição.
IL213625A0 (en) Combinations comprising methotrexate and dhodh inhibitors
BRPI1015471A2 (pt) ativador de gel relaxante
BR112013015891A2 (pt) uso de uma combinação, método de tratamento de um plasma e uso de uma combinação
EP2139883A4 (en) HIV-1 protease inhibitor
BRPI0914793A2 (pt) Composição, e, uso de uma composição
HUE040085T2 (hu) PDE7 inhibitorok alkalmazása mozgási rendellenességek kezelésére
ZA201007129B (en) Limk2 inhibitors,compositions comprising them,and methods of their use
EP2237793A4 (en) CATHEPSIN-B INHIBITORS
IL215835A0 (en) Carboxamide compounds and their use as calpain inhibitors
GB0820856D0 (en) Novel inhibitors of flavivirus replication
BRPI1006953A2 (pt) composição farmacêutica, e, uso de uma composição
ZA201204496B (en) Carboxamide compounds and their use as calpain inhibitors
BRPI0906721A2 (pt) Processo para fazer restauração dental, restauração dental, e processo para fazer uma restauração dental

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.